

**Recombinant Human IGF-BP5**  
**Catalog # PBG10174****Specification**

---

**Recombinant Human IGF-BP5 - Product Information****Recombinant Human IGF-BP5 - Additional Information****Description**

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.

**BiologicalActivity**

The  $ED_{50}$  was determined by its ability to inhibit IGF-II induced proliferation of MCF-7 is  $\leq 0.3 \mu\text{g/ml}$  in the presence of 15 ng/ml of human IGF-II.

**Authenticity**

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

**Endotoxin**

Endotoxin level is  $<0.1 \text{ ng/} \mu\text{g}$  of protein ( $<1\text{EU/} \mu\text{g}$ ).

**Protein Content**

Verified by UV Spectroscopy and/or SDS-PAGE gel.

**Storage**

-20°C

**Precautions**

Recombinant Human IGF-BP5 is for research use only and not for use in diagnostic or therapeutic procedures.

**Recombinant Human IGF-BP5 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)

- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Recombinant Human IGF-BP5 - Images**